RemeGen Rises, Falls Along With Chinese Antibody Ambitions
Discipline, Deals Key?
Executive Summary
Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.